

FIG. 1





FIG. 2



A





FIG. 3

FIG. 3 (con't)



B

FIG. 4

A




FIG. 4 (con't)




FIG. 5




FIG. 6








FIG. 7





B



A

FIG. 8

FIG. 9




FIG. 10




FIG. 11





FIG. 11 (con't)

C



D




FIG. 11 (con't)

E




FIG. 12




FIG. 13





FIG. 14



A20




FIG. 15 (con't)




FIG. 16




FIG. 16 (con't)

B16F10






FIG. 17

FIG. 17 (con't)

	Whole cell	AH1	UV Rag
HSV-1/ICP34.5/ICP47/mFLT3L/mL12 vs control	P < 0.0001	P<0.0001	P = 0.011
HSV-1/ICP34.5/ICP47/mFLT3L/mL12 vs HSV-1/ICP34.5/ICP47/mGMCSF	P = 0.0008	Ns; p = 0.105	P = 0.038
HSV-1/ICP34.5/ICP47/mGMCSF vs control	Ns; p = 0.078	Ns; p = 0.498	Ns; p = 0.8196

FIG. 18




FIG. 18 (con't)




FIG. 18 (con't)

A20





FIG. 18 (con't)



GROUP	MEDIAN SURVIVAL	SUBJECTS TUMOR-FREE Injected	SUBJECTS TUMOR-FREE Contralateral
Control	28	2	2
HSV-1/ICP34.5/ICP47-/mGMCSF 3e4 pfu	32	7	2
HSV-1/ICP34.5/ICP47-/mFLT3L/mL12 3e4 pfu	53	10	5
HSV-1/ICP34.5/ICP47-/mGMCSF 3e5 pfu	51.5	9	4
HSV-1/ICP34.5/ICP47-/mFLT3L/mL12 3e5 pfu	51.5	9	3

Analysis utilized Kaplan-Meier estimator with Mantel-Cox logrank to compare curves

FIG. 19




FIG. 19 (con't)




FIG. 19 (con't)




FIG. 19 (con't)





FIG. 19 (con't)

GROUP	MEDIAN SURVIVAL	SUBJECTS CENSORED	SUBJECTS TUMOR-FREE (INJECTED)	SUBJECTS TUMOR-FREE (NON-INJECTED)
Control	16	0	0	0
HSV-1/ICP34.5/ICP47/mGMCSF 5e5 pfu	25	0	4	1
HSV-1/ICP34.5/ICP47-mFL T3L/mL12 5e5 pfu	32	0	2	0
HSV-1/ICP34.5/ICP47-mGMCSF 5e4 pfu	20	0	0	0
HSV-1/ICP34.5/ICP47-mFL T3L/mL12 5e4 pfu	20	0	2	0

Fig. 20



35/46






Fig. 20 (con't)

HSV-1/ICP34.5-
/ICP47-
/mFLT3L/mlL12
5e6

Fig. 20 (con't)



GROUP	MEDIAN SURVIVAL	SUBJECTS TUMOR-FREE (INJECTED)	SUBJECTS TUMOR-FREE (NON-INJECTED)
Control	20	0	0
HSV-1/ICP34.5-/mGMCSF 5e6 pfu	27	3	0
HSV-1/ICP34.5-/mFLT3L/mL12 5e6 pfu	undefined	7	3

Fig. 21




Fig. 21 (con't)





Fig. 21 (con't)



GROUP	MEDIAN SURVIVAL	SUBJECTS TUMOR-FREE (INJECTED)	SUBJECTS TUMOR-FREE (NON-INJECTED)
Control	20	0	0
Anti-PD1 mAb	32	0	0
HSV-1/ICP34.5-/ICP47-/mFLT3L/mIL12 5e6 pfu	32	9	0
Anti-PD1 mAb + HSV-1/ICP34.5-/ICP47-/mFLT3L/mIL12 5e6 pfu	undefined	14	1

Fig. 22





Fig. 22 (con't)






Fig. 23



Fig. 24




Fig. 24 (con't)





Fig. 24 (con't)



GROUP	MEDIAN SURVIVAL	SUBJECTS TUMOR-FREE Injected	SUBJECTS TUMOR-FREE Contralateral
Control	24	0	0
HSV-1/ICP34.5-/mFLT3L/mL12	32.5	6	1
Anti-4-1BB mAb	27	0	1
Anti-4-1BB mAb + HSV-1/ICP34.5-/mFLT3L/mL12	undefined	9	1

Analysis utilized Kaplan-Meier estimator with Mantel-Cox logrank

MC38